Login / Signup

Prognostic utility of serum NT-proBNP (fragments 1-76aa and 13-71aa) and galectin-3 in predicting death and re-hospitalisation due to cardiovascular events in patients with heart failure.

Xi ZhangYunxia WanNuwan KarunathilakaWandy ChanKaram KostnerGunter HartelAndrew J S CoatsJohn J AthertonChamindie Punyadeera
Published in: Heart and vessels (2023)
Patients with heart failure (HF) are at a higher risk of rehospitalisation. In this study, we investigated the prognostic utility of galectin-3 (Gal-3) and NT-proBNP fragments (1-76aa and 13-71aa) as biomarkers to predict outcomes for patients with HF. We collected blood samples from patients with HF (n = 101). Gal-3 and NT-proBNP fragments (1-76aa and 13-71aa) concentrations were measured by immunoassay. Survival analysis and Cox proportional regression models were used to determine the prognostic utility of Gal-3 and NT-proBNP fragments. In patients with increased baseline levels of NT-proBNP 1-76 the time to primary endpoint (cardiovascular death or re-hospitalisation) was significantly shorter (p = 0.0058), but not in patient with increased baseline levels of Gal-3 or NTproBNP 13-71 . Patients with increased levels of NT-proBNP 13-71aa at 1 month showed reduced time to the primary endpoint (p = 0.0123). Our findings demonstrated that Gal-3 and NT-proBNP can be used as prognostic biomarkers to stratify patients with HF.
Keyphrases
  • cardiovascular events
  • acute heart failure
  • cardiovascular disease
  • type diabetes
  • heart failure
  • metabolic syndrome
  • mass spectrometry
  • atrial fibrillation
  • skeletal muscle
  • atomic force microscopy